JP2024042072A5 - - Google Patents

Download PDF

Info

Publication number
JP2024042072A5
JP2024042072A5 JP2024014900A JP2024014900A JP2024042072A5 JP 2024042072 A5 JP2024042072 A5 JP 2024042072A5 JP 2024014900 A JP2024014900 A JP 2024014900A JP 2024014900 A JP2024014900 A JP 2024014900A JP 2024042072 A5 JP2024042072 A5 JP 2024042072A5
Authority
JP
Japan
Prior art keywords
seq
sequence
abp
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024014900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024042072A (ja
JP7745669B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2019/068820 external-priority patent/WO2020140084A1/en
Application filed filed Critical
Publication of JP2024042072A publication Critical patent/JP2024042072A/ja
Publication of JP2024042072A5 publication Critical patent/JP2024042072A5/ja
Priority to JP2025100129A priority Critical patent/JP7854093B2/ja
Application granted granted Critical
Publication of JP7745669B2 publication Critical patent/JP7745669B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024014900A 2018-12-27 2024-02-02 抗ctla-4結合タンパク質およびその使用方法 Active JP7745669B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025100129A JP7854093B2 (ja) 2018-12-27 2025-06-16 抗ctla-4結合タンパク質およびその使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862785659P 2018-12-27 2018-12-27
US62/785,659 2018-12-27
PCT/US2019/068820 WO2020140084A1 (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof
JP2021537082A JP7558949B2 (ja) 2018-12-27 2019-12-27 抗ctla-4結合タンパク質およびその使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021537082A Division JP7558949B2 (ja) 2018-12-27 2019-12-27 抗ctla-4結合タンパク質およびその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025100129A Division JP7854093B2 (ja) 2018-12-27 2025-06-16 抗ctla-4結合タンパク質およびその使用方法

Publications (3)

Publication Number Publication Date
JP2024042072A JP2024042072A (ja) 2024-03-27
JP2024042072A5 true JP2024042072A5 (cg-RX-API-DMAC7.html) 2024-10-18
JP7745669B2 JP7745669B2 (ja) 2025-09-29

Family

ID=71126610

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021537082A Active JP7558949B2 (ja) 2018-12-27 2019-12-27 抗ctla-4結合タンパク質およびその使用方法
JP2024014900A Active JP7745669B2 (ja) 2018-12-27 2024-02-02 抗ctla-4結合タンパク質およびその使用方法
JP2025100129A Active JP7854093B2 (ja) 2018-12-27 2025-06-16 抗ctla-4結合タンパク質およびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021537082A Active JP7558949B2 (ja) 2018-12-27 2019-12-27 抗ctla-4結合タンパク質およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025100129A Active JP7854093B2 (ja) 2018-12-27 2025-06-16 抗ctla-4結合タンパク質およびその使用方法

Country Status (12)

Country Link
US (2) US12421311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3902821A4 (cg-RX-API-DMAC7.html)
JP (3) JP7558949B2 (cg-RX-API-DMAC7.html)
KR (2) KR102970393B1 (cg-RX-API-DMAC7.html)
CN (2) CN114008071B (cg-RX-API-DMAC7.html)
AU (2) AU2019413366B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012588A2 (cg-RX-API-DMAC7.html)
CA (2) CA3124961C (cg-RX-API-DMAC7.html)
IL (2) IL284156B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007848A (cg-RX-API-DMAC7.html)
SG (1) SG11202106764YA (cg-RX-API-DMAC7.html)
WO (1) WO2020140084A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7296728B2 (ja) * 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
CN114008071B (zh) 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
US20230265192A1 (en) * 2020-07-02 2023-08-24 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
JP2024502035A (ja) * 2020-12-31 2024-01-17 ノヴァロック バイオセラピューティクス, リミテッド Tnfr2に対する抗体およびそれの使用
AU2022303528A1 (en) * 2021-07-02 2024-01-25 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
MX2024007054A (es) * 2021-12-10 2024-09-04 Merck Sharp & Dohme Llc Aglutinantes de mesotelina humana.
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20110166335A1 (en) 2000-06-30 2011-07-07 Corbin David R Xenorhabdus sp. genome sequences and uses thereof
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
WO2006029219A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
SMT201900242T1 (it) * 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
WO2015092394A1 (en) 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
PL3151921T3 (pl) * 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
CN114014930A (zh) * 2015-02-13 2022-02-08 索伦托药业有限公司 结合ctla4的抗体治疗剂
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
DK3303394T3 (da) * 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
AU2016370648B2 (en) * 2015-12-15 2023-03-09 OncoC4, Inc. Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
MX2019010156A (es) 2017-02-27 2020-01-09 Dragonfly Therapeutics Inc Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2.
IL270743B2 (en) * 2017-05-19 2024-09-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
CN114008071B (zh) 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
AU2020210614A1 (en) 2019-01-21 2021-08-26 Sanofi Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers
US20230265192A1 (en) 2020-07-02 2023-08-24 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2025128343A5 (cg-RX-API-DMAC7.html)
Wang et al. The state of the art of bispecific antibodies for treating human malignancies
JP2023543031A5 (cg-RX-API-DMAC7.html)
JP2020504076A5 (cg-RX-API-DMAC7.html)
JP2023123726A5 (cg-RX-API-DMAC7.html)
JP2019536430A5 (cg-RX-API-DMAC7.html)
JP2020063262A5 (cg-RX-API-DMAC7.html)
RU2018139811A (ru) Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства
Xiong et al. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody
JP2009541492A5 (cg-RX-API-DMAC7.html)
JP2023529842A5 (cg-RX-API-DMAC7.html)
JP2023515223A5 (cg-RX-API-DMAC7.html)
JP2013527761A5 (cg-RX-API-DMAC7.html)
JP2021523913A5 (cg-RX-API-DMAC7.html)
JP2019513777A5 (cg-RX-API-DMAC7.html)
JP2020515247A5 (cg-RX-API-DMAC7.html)
JP2011207882A5 (cg-RX-API-DMAC7.html)
JP2023536461A5 (cg-RX-API-DMAC7.html)
JP2024520666A5 (cg-RX-API-DMAC7.html)
JP2024016024A5 (cg-RX-API-DMAC7.html)
JP2022540806A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
RU2010132956A (ru) Ангиопоэтин-2-специфические связывающие агенты
JP2024541680A5 (cg-RX-API-DMAC7.html)
JP2022543658A5 (cg-RX-API-DMAC7.html)